Medicines Co. wins interim patent extension; Sepracor grants Glenmark Lunesta license;

@FiercePharma: FDA slaps Novartis for Facebook widget. Article | Follow @FiercePharma

> Medicines Co. said the U.S. Patent and Trademark Office granted a one-year interim patent extension for its lead drug Angiomax, after a federal judge ruled that the patent office has to consider the company's extension application. Report

> Roche's Avastin helps patients with the most common form of lung cancer live longer than any other treatment, a new trial showed, giving the drug a boost after a slew of setbacks. News

> Glenmark Pharmaceuticals signed a settlement and license agreement with Sepracor to market a generic version of its sleep drug Lunesta. Story

> Sixty-three percent of surveyed gastroenterologists in the U.S. say they are prescribing Abbott/Eisai's blockbuster arthritis treatment Humira (adalimumab) off-label for the treatment of ulcerative colitis. Item

> Medicis Pharmaceutical said its second-quarter profit more than doubled as sales soared for the drug company's acne products. Article

> Sanofi-Aventis has once again selected contract manufacturing organisation SCM Pharma for the fast-tracked fill/finish of a radio-labeled product. Story

Biotech News

 @FierceBiotech: GSK licenses Vectura's inhalation tech for $32 million. Article | Follow @FierceBiotech

 @JohnCFierce: Another example of a weak biotech IPO. NuPathe cuts price from $14 to $16 to $10. Article | Follow @JohnCFierce

> Did the odds just get worse for Arena's new weight drug? Story

> Curis shares sink as Genentech evaluates lead drug's fate. Article

> Lambda snags Biovail's Toronto CRO. Story

Biotech IT News

> Online tool aid patient access to experimental drugs. News

> Adaptive trial modeling solution aids dose-finding. Report

> Michigan researchers to gain in IT makeover. Item

> Mayo Clinic to launch center for social media. Story

> Healthcare reform drives investor to IT opportunities. Article

> FDA, Tox21 try IT in place of animal tests. Item

And Finally... Pfizer may have turned around Wall Street's negative sentiment toward its pharmaceutical fortunes with one good quarter. Report

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

With a new CEO at Endo taking the reins, the drugmaker hopes its financial performance will save it from bankruptcy tied to its opioid litigation.